Results for nedonošenčkov translation from Slovenian to English

to še posebej velja pri dojenju novorojenčkov ali nedonošenčkov.
because insufficient information is available regarding the use of ramipril during breastfeeding (see section 5.2), ramipril is not recommended and alternative treatments with better established safety profiles during breast-feeding are preferable, especially while nursing a newborn or preterm infant.

novorojenčkov s hiperbilirubinemijo in nedonošenčkov se ne sme zdraviti s ceftriaksonom.
hyperbilirubinaemic newborns and preterm newborns should not be treated with ceftriaxone.

glavna razloga za vitrektomijo sta bila odstop mrežnice in retinopatija nedonošenčkov.
the main reasons for vitrectomy were retinal detachment and retinopathy of prematurity.

v prvi študiji je vseh 153 nedonošenčkov prejelo obe obliki v različnih zaporedjih.
in the first study, all 153 premature infants received both formulations in different sequences.

pri teh 3 serotipih je bil delež nedonošenčkov z odzivom pomembno manjši kot pri donošenčkih.
for these 3 serotypes, the proportion of responders among preterm infants was significantly lower than among term infants.

preglednica 1 neželeni učinki v profilaktičnih kliničnih raziskavah nedonošenčkov in otrok z bronhopulmonalno displazijo
table 1 undesirable effects in prophylactic clinical studies with premature and bronchopulmonary dysplasia paediatric populations

v pljučih in ledvicah teh umrlih nedonošenčkov so opazili usedline ceftriakson - kalcijeve soli.
precipitations of ceftriaxone – calcium salt have been observed in lungs and kidneys of these dead preterm newborns.

v večji objavljeni študiji so kofein citrat primerjali s placebom pri zdravljenju 2 006 nedonošenčkov z apnejo.
a large published study compared caffeine citrate with placebo in treating 2,006 premature babies with apnoea.

poleg tega je 19.466 otrok in 116 nedonošenčkov v 2. letu življenja dobilo obnovitveni odmerek cepiva synflorix.
furthermore, 19,466 children and 116 preterm infants received a booster dose of synflorix in the second year of life.

v drugi študiji je 211 in 202 nedonošenčkov ali otrok s kronočno pljučno boleznijo prejemalo palivizumab v tekoči oziroma liofilizirani obliki.
in the second study, 211 and 202 premature infants or children with chronic lung disease received liquid and lyophilised palivizumab, respectively.

teratogeni potencial in učinki na sposobnost razmnoževanja, ki so jih opazili pri živalih, niso pomembni za indikacijo v skupini nedonošenčkov.
teratogenic potential and effects on reproductive performance observed in animals are not relevant to its indication in the preterm infant population.

v kliničnih študijah je cepivo rotateq prejelo približno 1. 000 nedonošenčkov, rojenih od 25. do 36. tedna nosečnosti.
in a clinical study, rotateq was administered to approximately 1,000 infants who were born at a gestational age of 25 to 36 weeks.

zdravljenje z zdravilom pedea se izvaja le v neonatalnih oddelkih za intenzivno nego pod nadzorom izkušenega neonatologa (zdravnika, specializiranega za zdravljenje nedonošenčkov).
treatment with pedea should only be carried out in a neonatal intensive care unit under the supervision of an experienced neonatologist (doctor specialising in premature babies).

učinek na odstotek posteriornega odstopa steklovine, stopnjo utekočinjenosti steklovine, odstotek takojšnje postoperativne ponovne povezanosti mrežnice, razvoj proliferativne vitreoretinopatije ali stadij retinopatije nedonošenčkov pri zdravljenju z okriplazminom ni bil dokazan.
treatment with ocriplasmin did not demonstrate an effect on posterior vitreous detachment rate, vitreous liquefaction grade, immediate postoperative retinal reattachment rate, development of proliferative vitreoretinopathy, or stage of retinopathy of prematurity.

v kurativnem kliničnem preskušanju, v katerega je bilo vključeno 175 nedonošenčkov, z gestacijsko starostjo manj kot 35 tednov, je bila pogostnost bronhopulmonalne displazije, pri starosti 36 tednov po spočetju, 13/81 (16 %) za indometacin proti 23/94 (24 %) za ibuprofen.
in a clinical curative trial involving 175 preterm newborn infants less than 35 weeks of gestational age, the incidence of bronchopulmonary dysplasia at 36 weeks post-conceptional age was 13/81 (16%) for indomethacin versus 23/94 (24%) for ibuprofen.